Exploiting mesoporous silica, silver and gold nanoparticles for neurodegenerative diseases treatment
Copyright © 2022 Elsevier B.V. All rights reserved..
Neurodegenerative diseases (NDs) are considered public health problem characterized by neural loss causing cognitive and behavioral impairments. It is currently possible to use drugs capable of controlling the symptoms caused by these diseases. However, treatment is not able to prevent neural loss. In addition, poor solubility, low bioavailability due to the inability for crossing the blood-brain barrier (BBB) are described as the main limitations of the treatment. Nanotechnology involves the development of nanoscale drug delivery systems and they have been employed to optimize therapeutics face to several diseases treatment. In light of this, this review describes the highlights on the fabrication of nanotechnology-based drug delivery systems emphasizing mesoporous silica, gold and silver nanoparticles (MSNs, AuNPs and AgNPs, respectively) and their biological behavior for the treatment of Alzheimer's and Parkinson diseases (ADs and PDs, respectively).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:624 |
|---|---|
| Enthalten in: |
International journal of pharmaceutics - 624(2022) vom: 25. Aug., Seite 121978 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ribeiro, Taís C [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 16.08.2022 Date Revised 16.08.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijpharm.2022.121978 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343128713 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343128713 | ||
| 003 | DE-627 | ||
| 005 | 20231226015717.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijpharm.2022.121978 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1143.xml |
| 035 | |a (DE-627)NLM343128713 | ||
| 035 | |a (NLM)35792231 | ||
| 035 | |a (PII)S0378-5173(22)00533-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ribeiro, Taís C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Exploiting mesoporous silica, silver and gold nanoparticles for neurodegenerative diseases treatment |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.08.2022 | ||
| 500 | |a Date Revised 16.08.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier B.V. All rights reserved. | ||
| 520 | |a Neurodegenerative diseases (NDs) are considered public health problem characterized by neural loss causing cognitive and behavioral impairments. It is currently possible to use drugs capable of controlling the symptoms caused by these diseases. However, treatment is not able to prevent neural loss. In addition, poor solubility, low bioavailability due to the inability for crossing the blood-brain barrier (BBB) are described as the main limitations of the treatment. Nanotechnology involves the development of nanoscale drug delivery systems and they have been employed to optimize therapeutics face to several diseases treatment. In light of this, this review describes the highlights on the fabrication of nanotechnology-based drug delivery systems emphasizing mesoporous silica, gold and silver nanoparticles (MSNs, AuNPs and AgNPs, respectively) and their biological behavior for the treatment of Alzheimer's and Parkinson diseases (ADs and PDs, respectively) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Drug delivery systems | |
| 650 | 4 | |a Mesoporous silica nanoparticles | |
| 650 | 4 | |a Neurodegenerative diseases treatment | |
| 650 | 4 | |a Silver and gold nanoparticles | |
| 650 | 4 | |a Smart nanocarriers | |
| 650 | 7 | |a Silver |2 NLM | |
| 650 | 7 | |a 3M4G523W1G |2 NLM | |
| 650 | 7 | |a Gold |2 NLM | |
| 650 | 7 | |a 7440-57-5 |2 NLM | |
| 650 | 7 | |a Silicon Dioxide |2 NLM | |
| 650 | 7 | |a 7631-86-9 |2 NLM | |
| 700 | 1 | |a Sábio, Rafael M |e verfasserin |4 aut | |
| 700 | 1 | |a Carvalho, Gabriela C |e verfasserin |4 aut | |
| 700 | 1 | |a Fonseca-Santos, Bruno |e verfasserin |4 aut | |
| 700 | 1 | |a Chorilli, Marlus |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of pharmaceutics |d 1992 |g 624(2022) vom: 25. Aug., Seite 121978 |w (DE-627)NLM07779785X |x 1873-3476 |7 nnns |
| 773 | 1 | 8 | |g volume:624 |g year:2022 |g day:25 |g month:08 |g pages:121978 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijpharm.2022.121978 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 624 |j 2022 |b 25 |c 08 |h 121978 | ||